To prevent attacks, known heterozygotes should avoid harmful drugs and other triggers (e.g., nutritional alterations) whenever possible.[16]Wang B, Bonkovsky HL, Lim JK, et al. AGA clinical practice update on diagnosis and management of acute hepatic porphyrias: expert review. Gastroenterology. 2023 Mar;164(3):484-91.
https://www.gastrojournal.org/article/S0016-5085(22)01356-7/fulltext?referrer=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F
http://www.ncbi.nlm.nih.gov/pubmed/36642627?tool=bestpractice.com
[23]Balwani M, Wang B, Anderson KE, et al. Acute hepatic porphyrias: recommendations for evaluation and long-term management. Hepatology. 2017 Oct;66(4):1314-22.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605422
http://www.ncbi.nlm.nih.gov/pubmed/28605040?tool=bestpractice.com
British Porphyria Association
Opens in new window
American Porphyria Foundation
Opens in new window
European Porphyria Network
Opens in new window Generally, a well-balanced diet containing enough calories to maintain body weight and 60% to 70% of total calories as carbohydrate is recommended.
Cyclic attacks in women can be prevented by giving treatment with a gonadotrophin-releasing hormone (GnRH) analogue, which should be started during days 1 to 3 of the menstrual cycle.[10]Anderson KE, Spitz IM, Bardin CW, et al. A GnRH analogue prevents cyclical attacks of porphyria. Arch Int Med. 1990 Jul;150(7):1469-74.
http://www.ncbi.nlm.nih.gov/pubmed/2196028?tool=bestpractice.com
With long-term use, add-back oestrogen in the form of a low-dose skin patch helps prevent bone loss.
Haemin infusions once or twice weekly and givosiran (an interfering RNA therapeutic targeted to hepatic delta-aminolevulinic acid synthase) can prevent cyclic or non-cyclic attacks.[6]Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005 Mar 15;142(6):439-50.
http://www.ncbi.nlm.nih.gov/pubmed/15767622?tool=bestpractice.com
[26]Marsden JT, Guppy S, Stein P, et al. Audit of the use of regular haem arginate infusions in patients with acute porphyria to prevent recurrent symptoms. JIMD Rep. 2015 Mar 12;22:57-65.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486272
http://www.ncbi.nlm.nih.gov/pubmed/25762493?tool=bestpractice.com
[23]Balwani M, Wang B, Anderson KE, et al. Acute hepatic porphyrias: recommendations for evaluation and long-term management. Hepatology. 2017 Oct;66(4):1314-22.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605422
http://www.ncbi.nlm.nih.gov/pubmed/28605040?tool=bestpractice.com
[25]Ventura P, Bonkovsky HL, Gouya L, et al. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int. 2022 Jan;42(1):161-72.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299194
http://www.ncbi.nlm.nih.gov/pubmed/34717041?tool=bestpractice.com
Medical alert bracelets and wallet cards can remind patients and medical personnel of the diagnosis when other illnesses develop and during emergencies. This helps avoid treatment with medications that may exacerbate acute porphyrias.